Esther Gramage Selected Research

pleiotrophin (HARP)

1/2022	Metabolomics and biochemical alterations caused by pleiotrophin in the 6-hydroxydopamine mouse model of Parkinson's disease.
6/2021	Role of Receptor Protein Tyrosine Phosphatase β/ζ in Neuron-Microglia Communication in a Cellular Model of Parkinson's Disease.
11/2020	Role of RPTPβ/ζ in neuroinflammation and microglia-neuron communication.
1/2019	Pleiotrophin deletion alters glucose homeostasis, energy metabolism and brown fat thermogenic function in mice.
1/2018	Endogenous pleiotrophin and midkine regulate LPS-induced glial responses.
1/2017	Pleiotrophin regulates microglia-mediated neuroinflammation.
11/2016	Pleiotrophin overexpression regulates amphetamine-induced reward and striatal dopaminergic denervation without changing the expression of dopamine D1 and D2 receptors: Implications for neuroinflammation.
9/2015	Pleiotrophin modulates morphine withdrawal but has no effects on morphine-conditioned place preference.
12/2013	Phosphoproteomic analysis of the striatum from pleiotrophin knockout and midkine knockout mice treated with cocaine reveals regulation of oxidative stress-related proteins potentially underlying cocaine-induced neurotoxicity and neurodegeneration.
5/2012	The heparin binding growth factors midkine and pleiotrophin regulate the antinociceptive effects of morphine through α(2)-adrenergic independent mechanisms.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Esther Gramage Research Topics

Disease

7	Neuroinflammatory Diseases 01/2022 - 01/2016
5	Substance-Related Disorders (Drug Abuse) 01/2017 - 06/2008
4	Parkinson Disease (Parkinson's Disease) 01/2022 - 01/2011
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2017 - 04/2009
3	Gliosis 01/2016 - 10/2010
3	Pain (Aches) 09/2013 - 11/2010
2	Acute Pain 05/2012 - 11/2010
1	Wounds and Injuries (Trauma) 06/2021
1	Insulin Resistance 01/2019
1	Ataxia (Dyssynergia) 01/2018
1	Neuroblastoma 01/2018
1	Ischemia 01/2017
1	Cognitive Dysfunction 01/2016
1	Intractable Pain 05/2012
1	Chronic Pain 11/2010

Drug/Important Bio-Agent (IBA)

12	pleiotrophin (HARP)IBA 01/2022 - 04/2009
4	CytokinesIBA 01/2022 - 01/2016
4	Nerve Growth Factors (Neurotrophins)IBA 06/2021 - 11/2010
4	MidkineIBA 01/2018 - 05/2012
4	Amphetamine (Amfetamine)FDA LinkGeneric 11/2016 - 10/2010
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2018 - 01/2011
3	Opioid Analgesics (Opioids)IBA 09/2013 - 06/2008
3	Pharmaceutical PreparationsIBA 01/2011 - 04/2009
2	Protein Tyrosine PhosphatasesIBA 06/2021 - 01/2011
2	Glial Fibrillary Acidic ProteinIBA 01/2013 - 10/2010
2	Morphine (MS Contin)FDA LinkGeneric 05/2012 - 11/2010
1	Oxidopamine (6 Hydroxydopamine)IBA 01/2022
1	LipidsIBA 01/2019
1	Hypnotics and Sedatives (Sedatives)IBA 01/2018
1	Anaplastic Lymphoma KinaseIBA 01/2018
1	Ethanol (Ethyl Alcohol)IBA 01/2018
1	Toll-Like Receptor 4IBA 01/2017
1	Dopamine (Intropin)FDA LinkGeneric 11/2016
1	Annexin A7 (Synexin)IBA 04/2013
1	COP9 Signalosome ComplexIBA 04/2013
1	Aldehyde DehydrogenaseIBA 04/2013
1	Creatine Kinase (Creatine Phosphokinase)IBA 04/2013
1	Methamphetamine (Desoxyn)FDA LinkGeneric 04/2013
1	PhosphoproteinsIBA 04/2013
1	Heparin (Liquaemin)FDA LinkGeneric 05/2012
1	Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA 01/2011
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2011
1	Analgesics (Analgesic Drugs)IBA 11/2010
1	Class 5 Receptor-Like Protein Tyrosine PhosphatasesIBA 04/2009

Therapy/Procedure

2	Analgesia 09/2013 - 05/2012
1	Therapeutics 01/2019
1	Denervation 11/2016